L. Corsini

发表

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients

A. Russo, V. Bazan, V. Caló, 2020, Therapeutic advances in medical oncology.

Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells

A. Russo, E. Surmacz, V. Bazan, 2013, Journal of cellular physiology.

MUTYH-associated tumor syndrome: The other face of MAP

S. Vieni, V. Bazan, G. Pantuso, 2022, Oncogene.

Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells

A. Russo, V. Bazan, M. Terrasi, 2012, Journal of cellular and molecular medicine.

Impact of margin status on long-term results of liver resection for hepatocellular carcinoma: single-center time-to-recurrence analysis

D. Pagano, F. di Francesco, A. Seidita, 2019, Updates in Surgery.

Genetic and molecular characterization of the human Osteosarcoma 3AB‐OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness

F. Chiaradonna, A. Russo, V. Bazan, 2013, Journal of cellular physiology.

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

A. Russo, S. Vieni, V. Bazan, 2019, Advances in Therapy.

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer

V. Bazan, D. Fanale, A. Russo, 2022, Cancers.

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

D. Olive, S. Vieni, V. Bazan, 2022, Frontiers in Oncology.

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge

F. Guadagni, V. Bazan, V. Caló, 2021, ESMO open.

The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints

G. Cabibbo, C. Celsa, R. Cannella, 2022, Biomedicines.

Central Nervous System Malignancies

A. Inno, S. Gori, L. Incorvaia, 2021, Practical Medical Oncology Textbook.

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

A. Russo, V. Bazan, V. Caló, 2021, Frontiers in Oncology.

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

A. Russo, F. Fulfaro, N. Gebbia, 2010, Cancer treatment reviews.

The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies

A. Russo, V. Bazan, M. Terrasi, 2012, Expert opinion on therapeutic targets.

HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions

Giuseppe Cicero, A. Russo, V. Bazan, 2013, Breast Cancer Research and Treatment.

POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes

A. Russo, V. Bazan, D. Fanale, 2021, Oncogene.

Gene Signatures in CRC and Liver Metastasis

A. Russo, S. Rizzo, D. Fanale, 2012 .

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

A. Russo, V. Bazan, V. Caló, 2020, Cancers.

MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?

A. Russo, V. Bazan, G. Bronte, 2012, Oncogenesis.

Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors.

A. Russo, V. Bazan, D. Fanale, 2021, Critical reviews in oncology/hematology.

Monoclonal antibodies for the treatment of non-hematological tumors: a safety review

A. Russo, V. Bazan, F. Passiglia, 2018, Expert opinion on drug safety.

Biomarkers

P. Vigneri, V. Bazan, D. Fanale, 2021, Practical Medical Oncology Textbook.

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming

A. Russo, V. Bazan, J. Iovanna, 2020, Cancers.

Breast cancer genome-wide association studies: there is strength in numbers

V. Bazan, A. Russo, D. Fanale, 2012, Oncogene.

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?

A. Russo, V. Bazan, J. Iovanna, 2021, Cancers.

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength

A. Russo, V. Bazan, V. Caló, 2022, Frontiers in Oncology.

32P Can circulating immune checkpoints and KIT exon 11 mutations be prognostic factors in metastatic gastrointestinal stromal tumors?

V. Bazan, D. Fanale, L. Incorvaia, 2021, Annals of Oncology.

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer

A. Giordano, S. Vieni, V. Bazan, 2023, BMC Cancer.

Potential agnostic role of BRCA alterations in patients with several solid tumors: one for all, all for one?

V. Bazan, D. Fanale, C. Cipolla, 2023, Critical reviews in oncology/hematology.

Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

V. Bazan, G. Pantuso, D. Fanale, 2022, Critical reviews in oncology/hematology.

Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: looking for new tumor biological fingerprints.

G. Pantuso, D. Fanale, A. Russo, 2023, Critical reviews in oncology/hematology.